Mohammad Abdullah Zafar, MBBS
Associate Research ScientistCards
About
Research
Publications
2024
Efficacy of beta blockers in patients with thoracic aortic aneurysm: meta-analysis of randomized controlled trials
Tanriverdi L, Barrett A, Kalyanasundaram A, Zafar M, Ziganshin B, Elefteriades J. Efficacy of beta blockers in patients with thoracic aortic aneurysm: meta-analysis of randomized controlled trials. European Heart Journal 2024, 45: ehae666.2256. DOI: 10.1093/eurheartj/ehae666.2256.Peer-Reviewed Original ResearchThoracic aortic aneurysmRandomized controlled trialsPooled risk ratioB-blockersAortic aneurysmAortic dissectionControlled trialsAortic eventsRisk ratioPrimary outcomePooled risk estimatesRisk of aortic dissectionRisk of bias assessmentNo treatmentMeta-analysis of randomized controlled trialsInverse variance-weighted random-effects modelMeta-analysisLiterature searchB-blocker treatmentSystematic review protocolInternational Prospective RegisterCochrane Central Register of Controlled TrialsEfficacy of beta blockersCentral Register of Controlled TrialsSummary effect measuresGenetics of aortic aneurysm disease: 10 key points for the practitioner
Elefteriades J, Zafar M, Ziganshin B. Genetics of aortic aneurysm disease: 10 key points for the practitioner. JTCVS Open 2024, 21: 58-63. PMID: 39534337, PMCID: PMC11551243, DOI: 10.1016/j.xjon.2024.07.014.Peer-Reviewed Original ResearchSomatic Variants Acquired Later in Life Associated with Thoracic Aortic Aneurysms: JAK2 V617F
Waldron C, Zafar M, Ma D, Zhang H, Dykas D, Ziganshin B, Popa A, Jha A, Kwan J, Elefteriades J. Somatic Variants Acquired Later in Life Associated with Thoracic Aortic Aneurysms: JAK2 V617F. Genes 2024, 15: 883. PMID: 39062663, PMCID: PMC11276600, DOI: 10.3390/genes15070883.Peer-Reviewed Original ResearchThoracic aortic aneurysmDevelopment of thoracic aortic aneurysmAortic aneurysmJAK2 V617FMyeloproliferative neoplasmsSomatic variantsPrevalence of thoracic aortic aneurysmsDescending thoracic aortic aneurysmJAK2 V617F burdenAortic valve diseaseTarget of therapyDriver of myeloproliferative neoplasmsSurgical aortic replacementVariant allele fractionAscending thoracic aortic aneurysmAortic replacementAneurysm sizeAneurysm patientsValve diseaseVariant carriersIncreased riskJAK2 geneExome sequencing databaseAllele fractionAneurysmPatient-specific ascending aortic intervention criteria
Kalogerakos P, Zafar M, Li Y, Ellauzi H, Mukherjee S, Ziganshin B, Rizzo J, Elefteriades J. Patient-specific ascending aortic intervention criteria. European Journal Of Cardio-Thoracic Surgery 2024, 65: ezae162. PMID: 38632077, DOI: 10.1093/ejcts/ezae162.Peer-Reviewed Original ResearchAdverse aortic eventsRisk of adverse eventsAortic eventsAortic rootAneurysm patientsAscending aortaAdverse eventsIncreased risk of adverse eventsThoracic aortic aneurysm patientsAscending aortic aneurysmHigher risk of adverse eventsAortic aneurysm patientsAscending thoracic aortic aneurysm patientsBody surface areaGeneral populationPersonalized risk stratificationAortic diameterAneurysm locationRisk stratificationAortic aneurysmIncreased riskAscending diameterPatientsHigh riskZ-scoreGene Commonality in Arterial Circuits Throughout the Body
Harling L, Zafar M, Ziganshin B, Elefteriades J. Gene Commonality in Arterial Circuits Throughout the Body. Aorta 2024, 12: 008-012. PMID: 39532283, PMCID: PMC11606663, DOI: 10.1055/s-0044-1791667.Peer-Reviewed Original Research
2023
Intricacies of aortic risk assessment studies: not a simple matter
Zafar M, Wu J, Elefteriades J. Intricacies of aortic risk assessment studies: not a simple matter. European Heart Journal 2023, 45: 735-736. PMID: 38087929, DOI: 10.1093/eurheartj/ehad795.Peer-Reviewed Original ResearchMidterm follow-up of composite graft replacement of the aortic root (30-year experience)—remarkably safe, effective, and durable
Jeoffrey S, Zafar M, Velasco J, Khattak A, Ellauzi H, Nasir A, Kalyanasundaram A, Ziganshin B, Elefteriades J. Midterm follow-up of composite graft replacement of the aortic root (30-year experience)—remarkably safe, effective, and durable. JTCVS Open 2023, 17: 1-13. PMID: 38420531, PMCID: PMC10897671, DOI: 10.1016/j.xjon.2023.11.007.Peer-Reviewed Original ResearchAortic root replacementOperative mortalityTerm outcomesDistal aortic segmentsLong-term bleedingAortic root diseaseComposite graft replacementType A DissectionFirst-time operationsAge/genderARR patientsConcomitant CABGLate reoperationAcute typeRoot replacementAdverse eventsGraft failureGraft replacementRedo proceduresCabrol procedureUrgent operationAortic rootAortic segmentsPatientsOperative choiceDecision-making in aortic disease
Wu J, Zafar M, Elefteriades J. Decision-making in aortic disease. European Heart Journal 2023, 45: 633-634. PMID: 37936301, DOI: 10.1093/eurheartj/ehad699.Peer-Reviewed Original ResearchEvidence Accumulates: Patients with Ascending Aneurysms Are Strongly Protected from Atherosclerotic Disease
Waldron C, Zafar M, Ziganshin B, Weininger G, Grewal N, Elefteriades J. Evidence Accumulates: Patients with Ascending Aneurysms Are Strongly Protected from Atherosclerotic Disease. International Journal Of Molecular Sciences 2023, 24: 15640. PMID: 37958625, PMCID: PMC10650782, DOI: 10.3390/ijms242115640.Peer-Reviewed Original ResearchConceptsThoracic aortic aneurysmAortic aneurysmCarotid intima-media thicknessLow-density lipoprotein levelsIntima-media thicknessDevelopment of atherosclerosisMatrix metalloproteinase proteinsAscending aneurysmAortic calcificationAtherosclerotic diseaseLipoprotein levelsMyocardial infarctionLeading causeAneurysmsMetalloproteinase proteinsGrowth factorProtective relationshipDiseasePossible mechanismCurrent understandingMorbidityInfarctionAtherosclerosisPatientsPathophysiologyBicuspid Aortopathy is NOT More Virulent: Data from the Yale Aortic Institute
Zafar M, Ziganshin B, Elefteriades J. Bicuspid Aortopathy is NOT More Virulent: Data from the Yale Aortic Institute. Aorta 2023, 11: 1-18. DOI: 10.1055/s-0044-1787955.Peer-Reviewed Original Research